Advertisement
Research Article

Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

  • Jonathan Z. Li mail,

    Jli22@partners.org

    Affiliations: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Chanson J. Brumme,

    Affiliation: Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America

    X
  • Michael M. Lederman,

    Affiliation: Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America

    X
  • Zabrina L. Brumme,

    Affiliations: Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Simon Fraser University, Burnaby, British Columbia, Canada

    X
  • Hongying Wang,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • John Spritzler,

    Affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • Mary Carrington,

    Affiliations: Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc., NCI Frederick, Frederick, Maryland, United States of America

    X
  • Kathleen Medvik,

    Affiliation: Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America

    X
  • Bruce D. Walker,

    Affiliations: Harvard Medical School, Boston, Massachusetts, United States of America, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

    X
  • Robert T. Schooley,

    Affiliation: Division of Infectious Diseases, University of California San Diego, La Jolla, California, United States of America

    X
  • Daniel R. Kuritzkes,

    Affiliations: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • for the AIDS Clinical Trials Group A5197 Study Team
  • Published: March 30, 2012
  • DOI: 10.1371/journal.pone.0034134

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.